The Cambridge, Mass.-based drugmaker was developing revusiran for the treatment of hereditary amyloidosis with cardiomyopathy — a rare condition in which amyloid plaque collects in the organs and can cause heart failure, according to the report.
The company decided to suspend a Phase III trial of the drug after unblinded data from a previous trial “revealed an imbalance of mortality in the revusiran arm as compared to placebo,” according to a company statement.
Upon news of the halted drug development, Alnylam’s shares dropped more than 40 percent to $40.96 in post-market trading after closing at $70.30 on Wednesday.
More articles on supply chain:
FedEx to open new Ohio distribution center in 2017
Novartis restructures research unit, sheds 175 jobs: 4 things to know
Insmed buys AstraZeneca’s respiratory drug for $150M: 5 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
